Faron Pharmaceuticals Oy Director Dealing (8535K)
September 26 2016 - 10:59AM
UK Regulatory
TIDMFARN
RNS Number : 8535K
Faron Pharmaceuticals Oy
26 September 2016
Faron Pharmaceuticals Oy
("Faron" or the "Company")
Director Dealing
TURKU - FINLAND, 26 September 2016 - Faron Pharmaceuticals Oy
("Faron" or "Company") (LON: FARN), the clinical stage
biopharmaceutical company, today announces that Leopoldo
Zambeletti, a Non-Executive Director of the Company, purchased
4,000 ordinary shares in the capital of the Company at 250 pence
each on 23 September 2016.
Following this transaction, Leopoldo Zambeletti now holds 17,461
Ordinary Shares representing 0.07% of the issued share capital of
the Company.
ENDS
For more information please contact:
Faron Pharmaceuticals Oy
Katja Wallenlind
Phone +358 (50) 577 4807
E-mail: katja.wallenlind@faronpharmaceuticals.com
Hume Brophy, PR
Mary Clark, Eva Haas, Hollie Vile
Phone: +44 207 862 6390
E-mail: faron@humebrophy.com
Cairn Financial Advisers LLP, Nominated Adviser
Emma Earl, Tony Rawlinson, Rebecca Anderson
Phone: +44 207 148 7900
Panmure Gordon (UK) Limited, Joint Broker
Freddy Crossley, Duncan Monteith (Corporate Finance)
Tom Salvesen (Corporate Broking)
Phone: +44 207 886 2500
Whitman Howard Limited, Nominated Broker
Ranald McGregor-Smith, Francis North
Phone: +44 207 659 1234
About Faron Pharmaceuticals Oy
Faron is a clinical stage biopharmaceutical company developing
novel treatments for medical conditions with significant unmet
needs. The Company currently has a pipeline focusing on acute organ
traumas, cancer immunotherapy and vascular damage. The pipeline is
built on Faron's scientific knowledge and control of the
endothelial barrier, the membrane of cells lining blood and
lymphatic vessels to separate blood content from tissues. The
Company's lead candidate Traumakine(R) is in development for the
treatment of Acute Respiratory Distress Syndrome ("ARDS"), a rare,
severe, life-threatening medical condition characterised by
widespread inflammation in the lungs. Traumakine is currently in a
pan-European pivotal Phase III study (INTEREST). Additionally,
Faron is developing Clevegen(R) a ground breaking pre-clinical
anti-Clever-1 antibody. Clevegen has the ability to convert the
immune environment around a tumour from being immune suppressive to
immune stimulating. This novel macrophage-directed immuno-oncology
approach is called Tumour Immunity Enabling Technology ("TIET") and
can be used alone or in combination with other immune checkpoint
molecules for the treatment of cancer patients. New application
opportunities related to TIET cover chronic infections and
inefficient vaccination. Based in Turku, Finland, Faron
Pharmaceuticals is listed on AIM under the ticker 'FARN'. Further
information is available at www.faronpharmaceuticals.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHAKADPQBKDFCB
(END) Dow Jones Newswires
September 26, 2016 10:59 ET (14:59 GMT)
Faron Pharmaceuticals Oy (LSE:FARN)
Historical Stock Chart
From Apr 2024 to May 2024
Faron Pharmaceuticals Oy (LSE:FARN)
Historical Stock Chart
From May 2023 to May 2024